News | May 25, 2010

Balloon Catheter Offers Improved Trackability, Flexibility

May 25, 2010 – A balloon catheter technology with enhanced trackability and a redesigned tip for greater flexibility was recently cleared by the U.S. Food and Drug Administration (FDA) and received European CE mark. The noncompliant (NC) Quantum Apex percutaneous transluminal coronary angioplasty (PTCA) dilatation balloon catheter is being launched in European this week and the United States in June.

The NC Quantum Apex Catheter is a high-performance, post-dilatation balloon catheter developed specifically to address physicians’ needs in optimizing coronary stent deployment. Boston Scientific said it represents the next generation of its balloon catheter technology. It is available in a wide array of balloon diameters from 2 to 5 mm, with balloon lengths ranging from 6 to 30 mm. The monorail catheter platform will be available worldwide and both the monorail and over-the-wire (OTW) catheter platforms will be available in the United States.

The NC Quantum Apex Catheter performed very well, offering a noticeably lower profile, excellent trackability and effective post-dilatation,” said Jean Fajadet, M.D., director of the interventional cardiology, Clinique Pasteur, Toulouse, France. He was the first physician to treat patients with the new balloon catheter. “It features an innovative design and impressive performance that should benefit interventional cardiologists and their patients.”

Bruce Brodie, M.D., interventional cardiologist, Moses Cone Heart and Vascular Center, and chairman, LeBauer Cardiovascular Research Foundation, Greensboro, N.C., served as principal investigator of the POSTIT study. He was one of the first physicians in the United States to use the catheter. “Results from the POSTIT clinical study showed that more than 70 percent of coronary stents are not optimally deployed by a stent delivery balloon alone,” said Brodie. “The use of IVUS (intravascular ultrasound) with an adjunctive post-dilatation balloon makes it twice as likely that a stent will be optimally deployed. The NC Quantum Apex Catheter is a great addition to the available post-dilatation balloons, making it easier for physicians to achieve optimal stent deployment.”

For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init